PulmonarOM (Bacterial Lysates) in Respiratory Tract Infections
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
Primary
- To evaluate the efficacy of Pulmonaron in the decrease of interleukin-4/interferon gamma
after second period of treatment
Secondary
- To evaluate the efficacy of Pulmonarom in the prevention of upper respiratory tract
infections symptoms through patient evaluation of fever or respiratory presence after
second period of treatment
- To evaluate loss of working or study days after second period of treatment
- To evaluate the safety and tolerability of Pulmonarom in the population under study